October 2021 New Drug Approvals
Tavneos: TAVNEOS is a complement 5a receptor (C5aR) antagonist indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use. (1)
Scemblix: SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with: + Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs).This indication is approved under accelerated approval based on major molecular response (MMR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). + Ph+ CML in CP with the T315I mutation.(2)
Axum Rx offers a drug pipeline management solution across pharmacy and medical benefit. With Axum Rx’s pipeline management solution, you can anticipate and mitigate the impact of the drug pipeline on your bottom line today!